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ABSTRACT
Inhibitors targeting epigenetic control points of oncogenes offer a potential mean 
of blocking tumor progression in small cell and non-small cell lung carcinomas (SCLC, 
NSCLC). OTX015 (MK-8628) is a BET inhibitor selectively blocking BRD2/3/4. OTX015 
was evaluated in a panel of NSCLC or SCLC models harboring different oncogenic 
mutations. Cell proliferation inhibition and cell cycle arrest were seen in sensitive 
NSCLC cells. MYC and MYCN were downregulated at both the mRNA and protein levels. 
In addition, OTX015-treatment significantly downregulated various stemness cell 
markers, including NANOG, Musashi-1, CD113 and EpCAM in H3122-tumors in vivo. 
Conversely, in SCLC models, weak antitumor activity was observed with OTX015, 
both in vitro and in vivo. No predictive biomarkers of OTX015 activity were identified 
in a large panel of candidate genes known to be affected by BET inhibition. In NSCLC 
models, OTX015 was equally active in both EML4-ALK positive and negative cell 
lines, whereas in SCLC models the presence of functional RB1 protein, which controls 
cell progression at G1, may be related to the final biological outcome of OTX015. 
Gene expression profiling in NSCLC and SCLC cell lines showed that OTX015 affects 
important genes and pathways with a very high overlapping between both sensitive 
and resistant cell lines. These data support the rationale for the OTX015 Phase Ib 
(NCT02259114) in solid tumors, where NSCLC patients with rearranged ALK gene or 
KRAS-positive mutations are currently being treated.
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INTRODUCTION
Lung cancer is the second most common cancer in 
adults and the main cause of cancer-related deaths [1]. 
Non-small cell lung carcinomas (NSCLC) account for 
approximately 80% of cases and include adenocarcinoma, 
squamous cell, and large cell carcinomas, while small 
cell lung carcinomas (SCLC) represent the other 20% of 
cases [2]. NSCLC and SCLC are distinct biologic, genetic 
and clinical diseases [2, 3]. Approximately 50%–60% 
of NSCLC patients have at least one identifiable driver 
mutation, with the most common mutations found in the 
Kirsten ras (KRAS) gene (25–30%) and the epidermal 
growth factor receptor (EGFR) gene (13–22%), along 
with translocations involving anaplastic lymphoma kinase 
(ALK) gene in another 5–6% cases [2–5]. On the other 
hand, SCLC is mainly characterized by the prevalence 
of inactivating mutations in tumor suppressor genes such 
as TP53, PTEN, and RB1, and activation of MYC family 
members [3]. 
The bromodomain (BRD) and extraterminal 
(BET) family are protein interaction modules that 
specifically recognize Ɛ-N-acetylated lysine residues 
[6, 7], composed of three ubiquitously expressed proteins, 
BRD2, BRD3 and BRD4, as well as the testis-specific 
BRDT. BRDs are common in nuclear proteins that 
regulate gene transcription and chromatin organization, 
and play a key function in recruiting these protein 
complexes to acetylated chromatin. Dysfunction of 
BRD-containing proteins has been linked to the 
development of cancer [8, 9] and research has recently 
focused on the therapeutic efficacy of a novel class of 
epigenetic compounds that selectively target BET proteins 
in human malignancies [10–12]. OTX015 (MK-8628) is 
a selective thienotriazolodiazepine BET inhibitor that 
competitively occupies the acetyl-binding pockets of 
BRD2/3/4, resulting in their release from active chromatin 
and suppression of downstream signaling to RNA 
polymerases [13–15]. OTX015 has shown potent in vitro 
and in vivo antitumor activity against a range of cell lines 
derived from hematologic malignancies [14, 16] and solid 
tumors including neuroblastoma, glioblastoma, breast and 
prostate cancers [15, 17–20]. In some models, OTX015 
biological activity was shown to modulate transcriptional 
pathways characteristic of MYC functioning, however 
overt effects on other key transcriptional pathways 
such as AP-1 and NF-kB were also observed [14]. An 
inhibitory effect on MYCN function has been reported 
in translational models of neuroblastoma [15]. OTX015 
is the first BET inhibitor to have moved into the clinic, 
with three phase Ib clinical trials initiated in hematologic 
malignancies (NCT01713582) [21, 22], selected solid 
tumors (NCT02259114) and glioblastoma multiforme 
(NCT02296476). 
We report here preclinical findings of the BET 
inhibitor OTX015 in NSCLC and SCLC cell lines 
harboring oncogenic mutations recurrently found in lung 
cancer patients. In NSCLC models, OTX015 was equally 
active in both EML4-ALK positive and negative cell lines 
harboring other oncogenic mutations. OTX015-exposure 
resulted in rapid and sustained downregulation of MYC 
or MYCN, together with an in vivo downregulation 
of stemness markers in sensitive NSCLC models. 
Conversely, we observed that despite broad amplification 
of MYC family genes, OTX015 did not show potent 
in vitro or in vivo antitumor effects in the SCLC models 
evaluated. 
RESULTS
OTX015 reduces cell proliferation and induces 
cell cycle arrest in NSCLC cell lines with or 
without the EML4-ALK translocation
OTX015 displayed antiproliferative effects in 
EML4-ALK negative and positive NSCLC cell lines 
(Table 1, detailed in Supplementary Table S2). After 
72 h exposure, two out five cell lines (HOP62, HOP92) 
displayed GI50 values below 0.5 µM, whereas H2228 
and H3122 cells presented GI50 values below 1.0 µM 
(0.63 and 0.70 µM, respectively). In addition, these four 
cell lines displayed Emax values from 35% to 58% after 
72 h-exposure. On the other hand, A549 cells presented 
a GI50 > 6 µM and an Emax of 82%. The OTX015-resistant 
A549 cell line presents both KRAS and LKB1 mutated 
genes (Table 1). OTX015 was more potent than JQ1 
following 72 h-exposure in all five cell lines. OTX015 
inhibited cell proliferation in sensitive cell lines at in vitro 
concentrations that are achievable in plasma samples 
of patients treated with nontoxic OTX015 doses in an 
ongoing Phase I study in hematologic malignancies [23]. 
To determine if OTX015 exerts cytostatic effects 
in NSCLC cells, as previously described for other adult 
cancers [14, 17, 20] we evaluated cell cycle regulation 
after 500 nM OTX015 treatment in three OTX015-
sensitive cell lines (HOP92, H2228 and H3122) and one 
resistant model (A549). After 24 h-treatment a decrease 
in cells in the S phase was seen in H2228 and H3122 
cell lines, while then after 72 h of OTX015-exposure 
in HOP92 cells a significant increase in the percentage 
of cells in G1, along with a decrease in the percentage 
of cells in the S phase were seen (p < 0.05) (Figure 1A) 
after 72 h-treatment. No modulation of cell cycle phases 
was observed at any time point for the OTX015-resistant 
cell line A549. Similar results were obtained with JQ1 
(data not shown).
The effect of 500 nM OTX015 on mRNA 
levels of MYC and MYCN were evaluated in the four 
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OTX015-sensitive and one resistant cell lines. As shown in 
Figure 1B, OTX015 treatment resulted in a rapid and 
sustained downregulation of MYC in HOP92 cells. 
MYCN was downregulated in HOP62 and H3122 after 
4 and 24 h, while in the resistant cell line, A549 after 
24 h only. On the other hand, it was upregulated in HOP92 
after 4 h but downregulated at 24 h (Figure 1B). At the 
protein level, MYC was downregulated after 24 h in the 
MYC amplified cell line HOP92, which was maintained 
up to 72 h (Figure 1C). MYCN protein was only detected 
in HOP62 and H3122 cell lines, where a transient decrease 
was observed after 24 h of treatment with recovery to 
baseline levels by 72 h in H3122 cells, whereas an increase 
was seen in HOP62 cells after 72 h.
The four OTX015-sensitive cell lines and one 
OTX015-resistant cell line were analyzed for putative 
predictive biomarkers of OTX015 activity. We first 
evaluated potential correlations between basal mRNA 
and protein levels of a panel of candidate markers. 
Basal mRNA levels of 14 genes implicated in BET 
signaling pathways and whose expression is known to be 
affected by BET inhibition [14, 31, 32] were evaluated: 
BRD2/3/4, MYC and MYCN, CDKN1A (P21), BCL2, 
HEXIM1, SESN3, MTHFD1L, and four genes coding 
for histones (HIST2H2BE, HIST1H2BJ, HIST1H2BK 
and HIST2H4A). At baseline, the five cell lines expressed 
detectable and widely variable levels of these 14 genes, 
without a clear correlation with OTX015 sensitivity 
(Supplementary Figure S1A). Analysis of basal protein 
levels in the five NSCLC cell lines also failed to reveal any 
clear correlations between OTX015 sensitivity and basal 
protein levels of BRD2, BRD3, BRD4, MYC, MYCN, 
cyclin D1, P21, BCL2 or p-Tyr705STAT3 (Supplementary 
Figure S1B). 
A correlation analysis between gene expression 
changes of the 14 genes after OTX015 treatment with 
drug sensitivity (Emax) did not show any identify any 
predictive markers in the NSCLC panel. Modulation of 
MYC, BRDs, HEXIM1, BCL2, CDKN1A, MTHFD1L, 
SESN3, HIST1H2BJ, HIST2H2BE and HIST1H2BK 
mRNA levels after 24 h with 500 nM OTX015 showed no 
correlative tendencies with OTX015 biological outcomes 
in our panel of sensitive and resistant NSCLC cell lines 
(Supplementary Figure S2A). Likewise, no correlations 
were apparent after 4 h for any of the genes evaluated 
(data not shown).
OTX015 abrogates in vivo growth of EML4-ALK 
(+) NSCLC tumors and downregulates MYC 
genes and stem cell markers
In H3122 xenografts, a significant reduction in 
tumor growth was observed with 50 mg/kg OTX015 
BID and crizotinib 25 mg/kg thrice weekly (p < 0.001 
at day 25 with respect to vehicle for both agents) 
(Figure 2A). On the basis of T/C%, OTX015 but not 
crizotinib was considered active (maximum T/C 42% and 
53% on day 24, respectively). No significant weight loss 
or overt signs of toxicity were observed with OTX015 
or crizotinib (Figure 2A, insert), with both treatments 
generally well tolerated. OTX015 levels were determined 
in plasma, tumor and normal muscle tissues of control 
and treated mice. Plasma concentrations were over 
500 nM, while slightly lower levels were found in tumor 
and normal tissue (~300 nM; Figure 2B).
Analysis of tumor gene expression in H3122-bearing 
mice at the end of treatment did not show significant 
variations for any of the OTX015 canonical targets 
Table 1: Antiproliferative effects of the BET inhibitor OTX015 in NSCLC and SCLC cell lines
Tumor 
type Cell line
OTX015 JQ1
GI50 [µM] 
(95% IC)
Emax  
(at 6 µM)
GI50 [µM] 
(95% IC)
Emax 
(at 6 µM)
KRAS 
Exon2
EGFR 
Exon 
20
PIK3CA 
Exon 20 LKB1 TP53 RB1
EML4-
ALK fusion 
protein
MYC 
Amplification
MYCN 
Amplification
NSCLC HOP92 0.11  (0.08–0.17) 54
0.38  
(0.31–0.47) 55 — Y –
NSCLC HOP62 0.10  (0.06–0.16) 58
0.42  
(0.38–0.59) 59 — — —
NSCLC A549 > 6 82 > 6 74 — — —
NSCLC NCI-H2228 0.63  (0.42–0.95) 35
3.42  
(1.31–8.92) w Y (Var 3) NEii NE
NSCLC NCI-H3122 0.70  (0.52–0.93) 41
2.87  
(1.89–4.37) 22 Y (Var 1) NE NE
SCLC NCI-H69 > 6 87 1.03  (0.51–2.07) 53 — — Y
SCLC NCI-H82 > 6 92 > 6 89 — Y —
SCLC DMS-79 > 6 84 > 6 83 — Y ii
SCLC DMS-114 0.12  (0.08–0.17) 54
0.79 
(0.51–1.24) 51 — — —
GI50 and Emax (at 6 µM) values for OTX015 and JQ1 after 72h-exposure, by MTT assay. Results represent the mean and 95%CI of at least three independent experiments performed in triplicate. The cell panel 
was characterized for KRAS, EGFR, PIK3CA, LKB1, TP53, RB1, EML4-ALK fusion protein and MYC and MYCN amplification. Red indicates mutation, blue is wild-type, Y = yes, and NE = not evaluated.
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BRD2, 3 and 4 with respect to vehicle-treated animals 
(Figure 2C), as observed after in vitro analyses in 
NSCLC cell lines following OTX015 exposure (data 
not shown). On the other hand, OTX015 treatment 
significantly decreased MYC and MYCN mRNA levels 
in H3122-tumors (p < 0.01 and p < 0.001). Conversely, 
we observed an increase in levels of these MYC family 
proteins in crizotinib-treated tumors. In light of these 
findings, and since most NSCLC-ALK-positive patients 
acquire resistance to crizotinib within a few months [5], 
we explored the combination of OTX015 with the ALK 
inhibitor crizotinib. Concomitant combination of OTX015 
with crizotinib showed additive effects (CI ≤ 1.1) after 48 
h in two EML4-ALK-positive NSCLC cell lines (H2228 
and H3122) (Supplementary Figure S3).
We also evaluated the effect of OTX015 on a panel of 
stemness markers in vivo, observing that OTX015 induced 
significant transcriptional downregulation of NANOG, as 
well as Musashi-1, CD113 and EpCAM in NSCLC tumors, 
while it did not have an effect on other pluripotency genes 
such as Oct4, CD44 and CD24 (Figure 2D).
OTX015 shows limited in vitro and in vivo 
activity in SCLC models, with MYC modulation 
in sensitive and resistant cell lines
Among the four SCLC models evaluated, only 
the DMS114 cell line had an OTX015 GI50 value below 
0.5 µM after 72 h-exposure, with all other cell lines being 
resistant (Table 1). Interestingly, we observed that SCLC 
Figure 1: (A) OTX015 induces cell cycle changes in OTX015-sensitive NSCLC cell lines. Effect of 500 nM OTX015 on cell 
cycle progression after 24 h in H2228 and H3122 and after 72 h in HOP92 and A549 cells, by FACScan, expressed as percent cells per cell 
cycle phase (*p < 0.05 for G0/G1 cell cycle phase, and #p < 0.05 for S phase). (B) OTX015 modulates MYC and MYCN mRNA levels 
in sensitive and resistant NSCLC cell lines. Effect of 500 nM OTX015 on MYC and MYCN mRNA levels after 4 and 24 h by qPCR, 
expressed as fluorescence intensity normalized to housekeeping genes. Results represent the mean ± SD of one representative experiment 
performed in duplicate (*p < 0.05, **p < 0.01, ***p < 0.001 respect to controls). (C) OTX015 effects on MYC and MYCN protein levels 
in NSCLC cell lines by Western blot. Cells were exposed to 500 nM OTX015 for up to 72 h. Results are representative of at least two 
independent experiments. β-actin was used as a loading control and densitometry analysis was done using Image J software.
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OTX015 resistant cells displayed mutation for RB1 
gene, mutation which was not observed in the sensitive 
one DMS114 (Table 1). Similar results were seen with 
OTX015 and JQ1 except for NCI-H69 which was more 
sensitive to JQ1 (Table 1). To determine if OTX015 exerts 
cytostatic effects in DMS114 cells, we evaluated cell cycle 
progression after 72 h OTX015 (500 nM) (Figure 3A), 
which revealed a significant increase in the percentage of 
DMS114 cells in the G0/G1 phase, along with a significant 
decrease in the number of cells in the S phase, with no 
effect detected in the other SCLC cell lines.
Analysis of potential downstream targets 
showed that OTX015 resulted in rapid and sustained 
downregulation of MYC in the OTX015-sensitive cell line 
Figure 2: (A) OTX015 in vivo effects in NSLCL-ALK(+) H3122-tumor bearing mice. Antitumor effects of 50 mg/kg OTX015, 
BID, 7 days ON, gavage or 25 mg/kg crizotinib, thrice weekly, gavage were compared with vehicle thrice weekly, gavage in H3122 
murine xenografts (n = 10 mice per group). Asterisks indicate significant differences in tumor mass between each single agent arm 
versus the vehicle-treated group (*p < 0.05, **p  <0.01 and ***p < 0.001). (B) OTX015 concentrations in plasma and tissue from H3122 
xenografts. OTX015 levels were evaluated in terminal plasma, peritumoral normal and tumor tissue from H3122-bearing mice treated with 
50 mg/kg OTX015 BID or vehicle for 25 days. Mice were sacrificed 4 h after the last administration. Results are expressed as mean ± SD. 
(C) Gene expression of BRDs and MYC family genes by qPCR in H3122 tumors after treatment with OTX015. Differences in gene 
expression between OTX015 (50 mg/kg OTX015) and crizotinib (25 mg/kg thrice weekly) with respect to controls were evaluated with 
one-way Anova followed by Dunnett's Multiple Comparison Test (**p < 0.01 and ***p < 0.001). (D) Gene expression of stem cell markers 
by qPCR in H3122 tumors after treatment with OTX015. Differences in gene expression between OTX015 and crizotinib with respect to 
controls were evaluated with one-way Anova followed by Dunnett's Multiple Comparison Test (*p < 0.05 and **p < 0.01).
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DMS114 (Figure 3B), whereas a sustained upregulation 
of MYC was observed in NCI-H69 cells. On other hand, 
no significant modulations were seen in MYCN after 
4 h, while it was downregulated in NCI-H69, DMS79 and 
DMS114 cells after 24 h (Figure 3B). At the protein level, 
MYC expression was downregulated after 24 h in DMS114 
cells, which was maintained through to 72 h. In NCI-H69, 
DSM79 and DMS114 cells, MYCN protein levels were 
downregulated after 48 h-exposure (Figure 3C).
As observed in NSCLC cell lines, no correlations 
were identified between the basal mRNA expression of 
BRD2, 3 or 4, histones (HIST2H2BE, HIST1H2BJ, 
HIST1H2BK and HIST2H4A), MYC, MYCN, BCL2, 
P21, HEXIM1, SESN3 and MTHFD1L nor after 24 h with 
OTX015 in SCLC cell lines (Supplementary Figure S2B). 
This should be considered in light of the fact that only one 
of the four cell lines evaluated was sensitive to OTX015 
in vitro.
Although OTX015 presented good oral 
bioavailability and pharmacokinetic properties in the 
in vivo murine xenografts (data not shown), no significant 
differences in tumor volume were seen between OTX015 
and vehicle mice after 28 days of in vivo OTX015 
treatment (Figure 3D). The median time for tumors to 
Figure 3: (A) OTX015 induces cell cycle changes in OTX015-sensitive SCLC DMS114 cells. Effect of 500 nM OTX015 on 
cell cycle progression after 72 h, by FACScan, expressed as percent cells per cell cycle phase (*p < 0.05 for G0/G1 cell cycle phase, and 
#p < 0.05 for S phase). (B) OTX015 modulates MYC and MYCN mRNA levels in sensitive and resistant SCLC cell lines. Effect of 500 nM 
OTX015 on MYC and MYCN mRNA levels after 4 and 24 h, by qPCR, expressed as fluorescence intensity normalized to housekeeping 
genes. Results represent the mean ± SD of one representative experiment performed in duplicate (*p < 0.05, **p < 0.01, ***p < 0.001 
respect to controls). (C) OTX015 effects on MYC and MYCN protein levels in SCLC cell lines by Western blot. Cells were exposed to 
500 nM OTX015 for up to 72 h. Results are representative of at least two independent experiments. β-actin was used as a loading control 
and densitometry analysis was done using Image J software. (D) OTX015 in vivo effects on tumor volume in DMS114 murine xenografts. 
Tumor volume was determined after 28 days of treatment with vehicle or 50 mg/kg OTX015, BID, 7 days ON, gavage (n = 10 mice per 
group). 
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reach 1000 mm3 was 14.1 and 19.3 days for the vehicle 
and OTX015-treated arms, respectively.
OTX015 affects key biologic pathways in 
sensitive NSCLC and SCLC cells 
Gene expression changes were evaluated by 
GEP in sensitive and resistant lung cancer cell lines 
exposed to OTX015 (500 nM) or DMSO for 2, 4, 8, 
12 or 24 h. OTX015 affected key biologic pathways in 
a time-dependent manner in both NSCLC sensitive and 
resistant cell lines (Figure 4, Supplementary Figures 
S4–S8, Supplementary Tables S3–S4). Downregulated 
transcripts were enriched for genes involved in cell 
cycle and apoptosis regulation, the NFKB/IFN/MYD88 
pathway, as well as MYC, STAT and MIR34b/C targets. 
Upregulated transcripts were enriched for genes involved 
in chromatin structure and TP53/TP63 targets. The most 
differentially expressed genes after OTX015 exposure 
included different class 1 and 2 histones-coding genes, 
IRF7, EFR3B, FOS, EGR1, FGFR3, HES6, NOTCH1, 
ID1, KLF2, GADD451, CDKN1A, BCL6, SERTAD1, 
XEXIM1, SESN3 and CDKN1A among the up-regulated 
and CCL2, IL7R, IL8, IL6, TP63, MYC, BCL2L1, BIRC3, 
JUND, TGFB2, BAMBI, AURKA, TFPI, HMG1A, 
JUND, MTHFD1L, MLKL, DKK1, VEGFC, PDGFC 
and E2F2 among the down-regulated (Supplementary 
Tables S3–S4). Unexpectedly based on the differences in 
term of GI50 values, these genes were largely overlapping 
with those changing also in the resistant NSCLC cells, 
but individual transcripts behaving differently could be 
identified. Resistant cells presented a reduced modulation 
of CDKN1A (less up-regulated), IL7R, IL6, CSF2, RUNX2 
(less down-regulated) [14, 26, 27], and, in accordance 
with the above-mentioned protein data, the early down-
regulation of MYC was not observed in the resistant setting 
but only in the sensitive cell lines. Genes coding for 
proteins supporting cancer cells survival or proliferation 
Figure 4: Heatmap of the average gene set expression of the most enriched gene sets among genes changing after 
exposure to OTX015 in lung cancer OTX015 sensitive cell lines. (A) NSCLC cell lines; (B) SCLC cell line. The top 50 most 
enriched gene sets among upregulated genes and the top 50 enriched gene sets among downregulated genes are shown. Gene set expression 
was calculated using GSVA. Y-axis: cell lines at different time points. The heatmap colors are not scaled and show the consistent increase 
(or decrease) of gene set expression in time. X-axis: top differentially expressed gene sets as assessed by GSEA. Gene sets were filtered for 
a minimal fold-change of > 0.15 and FDR < 0.05.
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such as FOXD1 or EIF5A appeared up-regulated in 
resistant and not in sensitive, while E-cadherin, CLDN7, 
MDK, PKDCC, and JAG1 were more down-regulated.
In SCLC cell lines, OTX015 also affected 
relevant biologic pathways and individual transcripts 
in a time-dependent manner (Figure 4, Supplementary 
Figures S4–S6 and S9–S10, Supplementary 
Tables S4–S5). Downregulated transcripts were enriched 
for genes involved in cell cycle and apoptosis regulation, 
NFKB/MYD88 pathways, as well as MYC and STAT4/5 
targets. Upregulated transcripts were enriched for genes 
involved in chromatin structure and TP53/TP63 targets. 
The most up-regulated genes after exposure to OTX015 
comprised genes coding for different class 1 and 2 histones, 
IRF7, CDKN1A, CDKN1C, BRD2, XEXIM1, SESN3, 
STAT3 FGFR3, MKNK2 and EGR1, while the most down-
regulated transcripts encompassed E2F2, EIF5A, DKK1, 
CCL2, TPM3, CA2, MUC1, KRAS, VEGFB, MTHFD1L, 
BCL2L1, AURKA, PDGFC, and PDE4D (Supplementary 
Tables S4–S5). Again, GEP signatures largely overlapped 
between sensitive and resistant cells (Supplementary 
Figures S9–S10). Since only one sensitive and one 
resistant SCLC cell lines were studied, the vast majority 
of differences might be due to the cell of origin. However, 
we could observe a different regulation of CDKN2D (P19), 
up-regulated in resistant cells, and of CDKN1C (P57), up-
regulated in the sensitive cells.
Finally, OTX015-induced changes in NSCLC 
and SCLC models strongly overlapped with OTX015 
signatures in diffuse large B cell lymphomas [14], with 
JQ1 signatures in NSCLC [24] and other tumor models 
[26, 28–30], and also partially overlapped with 
those of HDAC inhibitors (Figure 4, Supplementary 
Figures S4–S6). 
DISCUSSION
In this study, a panel of lung cancer models 
harboring a range of oncogenic mutations, MYC 
amplifications, and the fusion protein EML4-ALK, 
representing the most relevant clinical subtypes of NSCLC 
or SCLC were selected to evaluate the biological relevance 
of BET inhibition in lung cancer and to better define 
which subtypes have the potential to be more sensitive to 
BET inhibition. We hereby provide supporting evidence 
to explore this new therapeutic avenue of BET proteins 
inhibition in lung cancer. 
OTX015 demonstrated a range of antitumor activity 
with GI50 values in the submicromolar range in several 
NSCLC and SCLC models, displaying cytostatic activity. 
OTX015 treatment resulted in an accumulation of cells 
in the G1 phase and depletion of cells in the S phase in 
OTX015-sensitive cell lines. Our data were similar to what 
was reported with the OTX015 analog JQ1 in lung cancer 
models [24, 31, 32], although, in our hands, OTX015 
presented lower GI50 values than JQ1. 
Initially, cells harboring the EML4-ALK fusion 
protein were expected to be more sensitive to BET 
inhibition, which is known to be implicated in the 
dependency between the ALK and MYC pathways 
[33]. However, four NSCLC cell lines were found to be 
equally susceptible to BET inhibition independent of their 
KRAS and EGFR mutational status and of the chimeric 
oncogene EML4-ALK. These results were in accordance 
with previous studies showing that the presence of EGFR 
mutations does not affect BET activity [32]. In addition, 
our findings with the A549 cell line were coherent with a 
previous report showing that KRAS/LKB1 mutant models 
are resistant to JQ1 [32]. In sensitive NSCLC models, 
OTX015 resulted in a rapid and sustained downregulation 
of MYC (HOP92) or a transient MYCN downregulation 
(HOP62 and H3122). Given that MYC or MYCN were 
not altered by OTX015 treatment in the OTX015-sensitive 
H2228 cell line, it will be valuable to investigate other 
proto-oncogenes such as MYCL1, or FOSL1 for a 
potential role in the OTX015 mechanism of action, as 
described previously for JQ1 [24]. In vivo experiments 
confirmed that OTX015 prompted tumor regression in 
an EML4-ALK(+) NSCLC model, modulating both 
MYC and MYCN together with the down-regulation of 
several stem cells markers, in particular NANOG as well 
as Musashi-1, CD113 and EpCAM in NSCLC tumors, 
whereas little effect on other pluripotency genes such as 
Oct4, CD44 and CD24 was observed. In support of these 
findings, it was recently shown that BRD4 is critical for 
maintenance of stem cell pluripotency which primarily 
occurs through the regulation of NANOG expression with 
only minimal effects on other pluripotency genes such 
as Sox2, Oct4, and Klf4, and JQ1 exposure inhibits the 
BRD4 binding to NANOG promoter leading to a marked 
transcriptional downregulation of the expression of the 
gene, without affecting MYC  [11, 34]. 
Despite initial response to crizotinib, the majority 
of patients with ALK-rearranged tumors, relapse within 
12 months and develop resistance [35]. Treatment options 
after failure with crizotinib are limited. Here, OTX015 was 
more potent than crizotinib in the in vivo setting without 
apparent toxicity and additive effects were seen when the 
two agents were combined in vitro in two EML4-ALK(+) 
NSCLC models. Interestingly, we observed that in vivo, 
in contrast to OTX015, crizotinib upregulated MYC and 
MYCN transcripts. Studies exploring the positioning of 
OTX015 as second-line treatment after crizotinib-acquired 
resistance or for delaying crizotinib resistance appearance 
are merited. 
Based on the relevance of deregulation of MYC 
family members in SCLC [36], we hypothesized that 
SCLC models would be more susceptible to BRD 
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inhibition/MYC gene downregulation than other tumor 
types. Instead, we observed that OTX015 treatment 
only decreased MYC mRNA and protein levels in 
DMS114 cells, whereas the three other SCLC models 
were resistant to OTX015 (GI50 > 6 µM after 72 h) 
suggesting that sensitivity to OTX015 is not dependent 
on MYC modulation. In addition, no correlations were 
observed between SCLC cell lines harboring MYC gene 
amplification and OTX015 sensitivity. DMS114 cells 
harbor a wildtype RB1 gene while the three OTX015-
resistant cell lines carry an inactive RB1 mutant, which 
may be implicated in the outcome of BET inhibition in 
this type of lung tumor. This would be in accordance with 
the observation that lymphoma cell lines with a strong 
E2F gene expression signature present lower sensitivity 
to OTX015 [14]. 
Transcriptome analysis after OTX015 treatment 
revealed wide-ranging modulation in genes coding for 
several histones and several genes involved in cell cycle, 
cell growth, apoptosis and migration, surprisingly in both 
OTX015-sensitive and OTX015-resistant cell lines, and 
for both NSCLC and SCLC models. OTX015 signatures 
also largely overlapped with what reported for the same 
compound or for other BET inhibitors in different tumor 
models.
The observed gene expression changes were very 
similar to what observed with OTX015 or with other BET 
inhibitors in other tumor models [14, 15, 26, 30, 37]. 
OTX015 down-regulated genes involved in cell cycle 
and apoptosis regulation, NFKB/MYD88 pathways, as 
well as MYC targets, while the genes coding for proteins 
involved in chromatin structure were the most commonly 
up-regulated genes. The down-regulation induced by 
OTX015 on a series of individual transcripts might have 
positive clinical implications for patients with lung cancer: 
AURKA [38], KRAS, MYC [36], CDK6 [39], MUC1 [40], 
IL6 [41], CCL2 [42], IL7R [43], E2F2 [44], TGFB2 
(its receptor BAMBI was up-regulated after OTX015) [45], 
PDE4D [46], TPM3 [47], and CA2 [48].
Analysis of the gene expression changes after 
OTX015 also lead to two unexpected observations. 
First, exposure to OTX015 led to the up-regulation 
of genes that might reduce the anti-tumor activity of 
the BET inhibitor such as STAT3 and FGFR3 in both 
NSCLC and SCLC, NOTCH1 and its target HES6 in 
NSCLC, PIM2 in SCLCL: further studies are needed 
to understand the relationship between these genes and 
OTX015 and whether novel combinations with agents 
targeting these proteins can improve the response to the 
epigenetic compound. Second, despite big differences 
in terms of GI50 values, sensitive and resistant cell lines 
presented very similar gene expression changes after 
exposure to OTX015 given at 500 nM. Although our 
analyses encompassed only a limited number of resistant 
lung cancer cell lines, a few hints could be made on the 
mechanisms underlying primary resistance to OTX015. 
NSCLC resistant cells presented a reduced modulation of 
known BET inhibitors targets [14, 26, 27] such CDKN1A 
(less up-regulated), IL7R, IL6, CSF2, RUNX2 (less down-
regulated), and, in accordance with our protein data, the 
early down-regulation of MYC was observed only in the 
sensitive cell lines. After OTX015 SCLC resistant and 
sensitive cells differed presenting an up-regulation of 
CDKN2D (P19) in resistant cells, and of CDKN1C (P57) 
in the sensitive cells, changes that could be linked with the 
different sensitivity to anti-cancer drugs [49, 50].
Our findings indicate that the subsets of NSCLC 
cells harboring the EML4-ALK chimeric oncogene 
appear sensitive to BET inhibition. Also, concurrent 
mutations in KRAS and LKB1 (coding a serine-threonine 
kinase that directly phosphorylates and activates 
AMPK) genes abrogated OTX015 effects in NSCLC, 
as previously described for JQ1 [32]. In SCLC models, 
our findings highlighted that absence of expression of 
the product of RB1 (the retinoblastoma protein, pRB) 
as a consequence of deletion, mutation, chromosomal 
loss or other mechanisms, as is the case in almost 90% 
of SCLC patients, might be a resistance marker for BET 
inhibition in SCLC. In contrast to direct small-molecule 
inhibitors of driver oncoproteins where specific DNA 
mutations serve as reliable biomarkers, the establishment 
of predictive markers of BET inhibition is heavily affected 
by the underlying heterogeneous genetic and epigenetic 
landscape of human cancers, including lung cancers, 
that can lead to the activation of different driver genes in 
specific individual cancers, or even in different subclones 
of the same tumor [51]. BET bromodomain proteins can 
be expected to have different targets in cancers derived 
from different cells, and this may influence the activity 
and mechanism of action of BET inhibitors. Collectively, 
our findings indicate that the cellular context-dependent 
requirement of BET inhibition cannot be fully explained 
on the basis of the known molecular functions of BRDs, 
as also highlighted by largely overlapping gene expression 
changes in both sensitive and resistant cell lines, or the 
basal levels of MYC genes, and to date, no genetic, 
transcriptional or chromatin markers have been identified 
to predict responsiveness to BET inhibition, except the 
concurrent mutations in KRAS and LKB1 genes in lung 
carcinoma models [32]. 
In conclusion, we reported a broad-spectrum activity 
of OTX015 against NSCLC cell lines, but not in SCLC. 
OTX015 appears to be a promising therapeutic strategy 
for EML4-ALK positive patients as well as KRAS-mutant 
NSCLC patients with wildtype LKB1, whereas EGFR 
mutations did not correlate with the outcome of BET 
inhibition. In addition, OTX015 presented good oral 
bioavailability and induced tumor regression in EML4-
ALK(+) xenografts. It inhibited MYC expression however 
this was not related to its sensitivity in cancer cell lines. 
In addition, we provide a rationale for investigating 
OTX015 as a single agent and combined with crizotinib 
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in NSCLC-ALK(+) patients. These findings were the 
scientific support for the OTX015 dose escalation study in 
solid tumors including NSCLC patients (NCT02259114). 
MATERIALS AND METHODS
Cell culture and reagents
OTX015 (MK-8628) was provided as a powder by 
Oncoethix. It was dissolved in DMSO as a 10 mM stock 
solution and stored at −20°C. JQ1 was purchased from 
BPS Bioscience. Crizotinib, a protein tyrosine kinase 
inhibitor of the MET receptor and ALK-fusion protein, 
was purchased from Selleck Chem. Drug stock solutions 
were reconstituted according to supplier instructions. 
Reagents were purchased from Sigma-Aldrich unless 
otherwise specified.
H2228, NCI-H69, NCI-H82 and DMS79 cell 
lines were obtained from the American Type Culture 
Collection, HOP92, HOP62, A549 and DMS114 from 
the National Institute of Cancer, Bethesda, USA, while 
the H3122 cell line was a kind gift of Prof. Giorgio 
Inghirami. Cell lines were maintained in T-25 culture 
flasks in RPMI 1640 supplemented with 10% FBS 
(#26140079, Gibco FBS qualified USA origin, Life 
Technologies), 2 mM glutamine (PAA Laboratories), 
100 units/ml penicillin and 100 µg/ml streptomycin 
(PAA Laboratories) at 37°C in a humidified 5% CO2 
atmosphere. Cell lines with a passage number ranging 
from 5 and 40 were used and were maintained in culture 
for up to 6 weeks. Confirmation of cell identity and 
verification of Mycoplasma sp. contamination was 
performed by Idexx BioResearch (Germany). Cell 
counting was performed with a hemocytometer.
Cell cycle analyses
 5 × 105 cells were treated with 500 nM OTX015, 
JQ1 or equivalent concentrations of DMSO for 48 h, then 
stained with citrate buffer RNase (1 mg/ml) and propidium 
iodide (100 µg/ml) for 15 minutes at room temperature. 
DNA content and cell cycle distribution were analyzed by 
FACScan. Experiments were independently performed at 
least three times, unless otherwise indicated.
In vivo studies
6-week-old female nude Foxn1 mice were obtained 
from Harlan Laboratories (Udine, Italy) and maintained 
at a constant temperature and humidity, according to 
institutional guidelines. Protocols were approved by 
the ethics committee of the IRCCS-Istituto di Ricerche 
Farmacologiche Mario Negri, Italy. For the NSCLC 
model, mice were subcutaneously injected in the right 
flank with the H3122 EML4-ALK-positive cell line 
(107 cells/mouse). When tumors reached ~100 mg, 
mice were randomized to 1) vehicle: 0.5% methocel, 
thrice weekly, gavage; 2) 50 mg/kg OTX015, bi-daily 
(BID), 7 days ON, gavage; or 3) 25 mg/kg crizotinib, 
thrice weekly, gavage. For the SCLC model, DMS114 
tumor fragments were subcutaneously grafted in the 
right flank. When tumors reached ~100–150 mg, mice 
were randomized to: 1) vehicle (PBS, gavage) or 2) 
50 mg/kg OTX015, BID, 7 days ON, gavage. Tumor size 
measurements and mouse body weight were recorded at 
least twice a week from treatment start until the end of the 
study. Treatment efficacy was calculated as T/C%, where 
T and C are the mean tumor weight of treated and control 
groups, respectively. A T/C% < 45% was considered 
active. Tolerability was evaluated on the basis of body 
weight loss, clinical observation and mortality.
Quantification of OTX015 levels in plasma and 
tissue samples
OTX015 concentrations were determined 
using a validated Acquity Ultra Performance Liquid 
Chromatography System (Waters) coupled with a tandem 
mass spectrometry detection method (UPLC/MS/MS), as 
described previously [52]. In vivo OTX015 levels were 
analyzed in terminal plasma, peritumoral tissue, peripheral 
and tumor tissues from H3122 xenograft-bearing nude 
mice. Control and OTX015-treated mice were sacrificed 
4 h after the last treatment.
Gene expression profiling (GEP)
RNA samples isolated using Trizol extraction from 
2 × 106 cells treated with 500 nM OTX015 or 0.1% DMSO 
were processed using the Human HT-12 v4 Expression 
BeadChip (Illumina), as previously described [14]. Data 
processing and statistical analysis were performed using 
R/Bioconductor. Transcript mapping was based on HG19 
using manufacturer supplied annotation. Data were 
quantile normalized and differential expression analysis 
was performed using limma [53]. Functional annotation 
was performed using gene set enrichment analysis (GSEA) 
method using the GSEA gene sets [54], the Signature 
Database [55], and previously reported gene sets [14]. 
Differential expression of gene sets was calculated using 
the gene set variation analysis (GSVA) method [56]. The 
GEP data have been deposited in NCBI’s Gene Expression 
Omnibus [57] and are accessible through GEO Series 
accession number GSE72961 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc = GSE72961). 
Chou-Talalay combination studies
For combination studies, 20 × 103 cells/well were 
seeded in a 96-well plate and treated 48 h later with 
increasing concentrations of OTX015 alone or combined 
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with crizotinib at a range of concentrations. GI20, GI40, GI60 
and GI80 drug concentrations were evaluated. To assess 
drug-drug interactions, dose-response data were evaluated 
with the CalcuSyn program (Biosoft) which applies median 
effect methodology to estimate a combination index (CI), 
CI values < 0.9 indicate synergism, 0.9 to 1.1 indicate 
additive effects, and > 1.1 indicate antagonism [58].
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